Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists
暂无分享,去创建一个
[1] A. Kaptein,et al. Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies , 2015, Pituitary.
[2] T. J. Moore,et al. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. , 2014, JAMA internal medicine.
[3] M. Silber,et al. Impulse control disorders in patients with dopamine agonist‐treated prolactinomas and nonfunctioning pituitary adenomas: a case–control study , 2014, Clinical endocrinology.
[4] L. Stoeckel,et al. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study , 2014, Pituitary.
[5] G. Stalla,et al. Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. , 2012, European journal of endocrinology.
[6] P. Valkovič,et al. Impulse Control Disorders Associated With Dopaminergic Medication in Patients With Pituitary Adenomas , 2011, Clinical neuropharmacology.
[7] Alberto Fernández,et al. Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK) , 2010, Clinical endocrinology.
[8] W. Ludlam. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK) , 2010 .
[9] H. Falhammar,et al. Pathological gambling and hypersexuality in cabergoline‐treated prolactinoma , 2009, The Medical journal of Australia.
[10] D. Vinkers,et al. A case of mania after long-term use of quinagolide. , 2007, General hospital psychiatry.
[11] A. Beckers,et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. , 2006, The Journal of clinical endocrinology and metabolism.
[12] A. Colao,et al. Advances in the treatment of prolactinomas. , 2006, Endocrine reviews.
[13] M. Burns,et al. Case-Control Study , 2020, Definitions.
[14] P. Cappabianca,et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. , 2004, The Journal of clinical endocrinology and metabolism.
[15] G. Vitale,et al. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. , 2004, The Journal of clinical endocrinology and metabolism.
[16] R. Quinton,et al. Medical Therapy of Macroprolactinomas in Males: I. Prevalence of Hypopituitarism at Diagnosis. II. Proportion of Cases Exhibiting Recovery of Pituitary Function , 2001, Pituitary.
[17] D. Pauler,et al. Primary medical therapy of micro- and macroprolactinomas in men. , 2000, The Journal of clinical endocrinology and metabolism.
[18] C. Baird,et al. The pilot study. , 2000, Orthopedic nursing.
[19] C. Raftopoulos,et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. , 1999, The Journal of clinical endocrinology and metabolism.
[20] J. Webster,et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea , 1994, The New England journal of medicine.
[21] M. Bergsneider,et al. Acute psychosis in a woman with a prolactinoma. , 1987, International Journal of Neuroscience.